Ernst & Young study shows 85% of participating organization leaders are seeing better patient outcomes, and nearly 75% report ...

The pharmacy benefit manager (PBM) industry is under pressure to shift to models that avoid conflicts of interest and ...

In a new Wolters Kluwer report, it was revealed that 80% of respondents cited “optimizing workflows” as a top organizational ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

Ernst & Young study shows 85% of participating organization leaders are seeing better patient outcomes, and nearly 75% report ...

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...

Co-founder and chief clinical officer, InStride Health. InStride Health provides evidence-based care for children, teens and ...

Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article ...

While heritable human genome editing is banned in the United States, across Europe and much of the world, the technology ...

Although 52% of healthcare leaders believe a fatal cyber-related patient incident will happen within the next five years, ...

Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand ...

This number can be attributed to claim denials, high deductibles and the underutilization of digital tools available within ...